title: [Valdoxan in the treatment of depression in neurological practice: results of the Russian multicenter naturalistic study "Resonance"].
abstract: Efficacy and tolerability of valdoxan (agomelatin) in the treatment of mild and moderate depression caused by neurologic diseases (cerebrovascular disorders, neurocirculatory dystonia, chronic pain syndrome) were studied in a sample of 277 patients aged from 18 to 70 years (mean age 46.0±11.3 years), including 21.66% men and 76.53% women. Patients received valdoxan during 6 weeks. Symptoms of depression were arrested in 81.20% of patients. There was the decrease in signs of fatigability and the improvement of work effectiveness assessed by specific tests. Coefficient of mental stability reached normal values.
authors.forename: O V
authors.initials: OV
authors.lastname: Vorob'eva
mesh_terms: D000081:Acetamides / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D002561:Cerebrovascular Disorders / Q000150:complications; D059350:Chronic Pain / Q000150:complications; D003866:Depressive Disorder / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013577:Syndrome; D016896:Treatment Outcome; D055815:Young Adult; D009281:Naphthalenes
chemical_list: D000081:Acetamides; C084711:agomelatine; D009281:Naphthalenes